Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6043-6053

  Attia, Peter ^a   Phan, Giao Q ^a   Maker, Ajay V ^a   Robinson, Michael R ^a   Quezado, Martha M ^a   Yang, James C ^a   Sherry, Richard M ^a   Topalian, Suzanne L ^a   Kammula, Udai S ^a   Royal, Richard E ^a   Restifo, Nicholas P ^a   Haworth, Leah R ^a   Levy, Catherine ^a   Mavroukakis, Sharon A ^a   Nichol, Geoff ^a   Yellin, Michael J ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; HLA A ANTIGEN; IPILIMUMAB; CANCER VACCINE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN TUMOR; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; COLITIS; CORRELATION ANALYSIS; DERMATITIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ENTEROCOLITIS; EYE DISEASE; FEMALE; HEPATITIS; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSITIS; KARNOFSKY PERFORMANCE STATUS; LIVER DISEASE; LIVER TUMOR; LUNG TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RACEMIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; UVEITIS; VACCINATION; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROGNOSIS; SKIN TUMOR;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNITY; CANCER VACCINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 24944459890     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.205     Document Type: Article

References (42)

1. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 169:1042-1049, 1970
2. Jenkins MK, Ashwell JD, Schwartz RH: Allogeneic non-T spleen cells restore the responsive-ness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 140:3324-3330, 1988
3. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349-1356, 1990
4. Linsley PS, Brady W, Grosmaire L, et al: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173: 721-730, 1991
5. Koulova L, Clark EA, Shu G, et al: The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med 173:759-761, 1991
6. Linsley PS, Brady W, Urnes M, et al: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569, 1991
7. Brunet JF, Denizot F, Luciani MF, et al: A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267-270, 1987
8. Gross JA, Callas E, Allison JP: Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 149:380-388, 1992
9. Alegre ML, Frauwirth KA, Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220-228, 2002
10. Linsley PS, Greene JL, Brady W, et al: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801, 1994
11. Walunas TL, Bakker CY, Bluestone JA, et al: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541-2550, 1996
12. Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540, 1996
13. Brunner MC, Chambers CA, Chan FK, et ai: CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162:5813-5820, 1999
14. Greenwald RJ, Oosterwegel MA, van der Woude D, et al: CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366-373, 2002
15. Lindsten T, Lee KP, Harris ES, et al: Characterization of CTLA-4 structure and expression on human T cells. J Immunol 151:3489-3499, 1993
16. Walunas TL, Lenschow DJ, Bakker CY, et al: CTLA-4 can function as a negative regulator of cell activation. Immunity 1:405-413, 1994
17. Shevach E: CD4+CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2:389-400, 2002
18. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor, foxp3. Science 299:1057-1061, 2003
19. Khattri R, Cox T, Yasayko SA, et al: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337-342, 2003
20. Egen JG, Kuhns MS, Allison JP: CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618, 2002
21. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996
22. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95:10067-10071, 1998
23. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999
24. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
26. Phan GQ, Touloukian CE, Yang JC, et al: Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349-356, 2003
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
28. Robinson MR, Chan CC, Yang JC, et al: Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother 27:478-479, 2004
29. Pass HA, Schwarz SL, Wunderlich JR, et al: Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J Sci Am 4:316-323, 1998
30. Dudley ME, Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675, 2003
31. Vasu C, Prabhakar BS, Holterman MJ: Targeted CTLA-4 engagement induces CD44-CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol 173:2866-2876, 2004
32. Takahashi T, Tagami T, Yamazaki S, et al: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310, 2000
33. Taylor PA, Noelle RJ, Blazar BR: CD4(+) CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193:1311-1318, 2001
34. Waterhouse P, Penninger JM, Timms E, et al: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985-988, 1995
35. Chambers CA, Sullivan TJ, Allison JP: Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7:885-895, 1997
36. Tivol EA, Gorski J: Re-establishing peripheral tolerance in the absence of CTLA-4: Complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 169:1852-1858, 2002
37. Uchikoshi F, Yang ZD, Rostami S, et al: Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. Diabetes 48:652-657, 1999
38. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune diseases: A general susceptibility gene to autoimmunity? Genes Immun 1:170-184, 2000
39. Ariyan C, Salvalaggio P, Fecteau S, et al: Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression. J Immunol 171: 5673-5677, 2003
40. Greenwald RJ, Latchman YE, Sharpe AH: Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391-396, 2002
41. Chambers CA, Kuhns MS, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594, 2001
42. Sanderson K, Scotland R, Lee R, et al: Autoimmunity in a phase I Trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stage III and IV melanoma. J Clin Oncol 23:741-750, 2005